ConductScience.org, home

Comparison · NCT01343667-7597cdf5

GFRS EPD vs GEF EPD: Major Adverse Events (MAE)

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

2 sourcestrial-comparisons-2026-03-23-0.1.0

Download JSON
Cite this record

ConductScience Library. GFRS EPD vs GEF EPD: Major Adverse Events (MAE). Trial comparisons, record NCT01343667-7597cdf5. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT01343667-7597cdf5

On this page

Measures6

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

MeasureValue95% interval, lower95% interval, upperMethodNote
Risk in group 10.04660.02970.0725wilson
Risk in group 20.04170.03020.0571wilson
Risk difference, group 1 minus group 20.00497-0.0180.0332newcombe hybrid score
Risk ratio, group 1 over group 21.120.6441.95log
Odds ratio, group 1 over group 21.130.6312.01log
Number needed to treat, for one more participant with the outcome on GFRS EPD than on GEF EPD201from the risk difference intervalthe interval includes no difference

Groups2

Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.

GroupTitleDescriptionWith the outcomeAnalysedClinicalTrials.gov code
Group 1GFRS EPD
Carotid artery stenting with Gore Flow Reversal System embolic protection device~Gore Flow Reversal System: Embolic protection by the GORE Flow Reversal System during carotid artery angioplasty and stenting
18386OG000
Group 2GEF EPDCarotid artery stenting with Gore Embolic Filter embolic protection device~Gore Embolic Filter: Embolic protection by the GORE Embolic Filter during carotid artery angioplasty and stenting36864OG001

Outcome

Type
PRIMARY
Title
Major Adverse Events (MAE)
Description
Major Adverse Events include death, stroke and myocardial infarction
Time frame
Onset from start of index procedure to 30-day follow-up assessment
Population
Enrolled subjects with successful procedure and sufficient follow-up

Source ClinicalTrials.gov

Trial

Title
GORE Flow Reversal System and GORE Embolic Filter Extension Study
NCT number
NCT01343667
Phases
NA
Conditions
Carotid Stenosis, Constriction, Pathologic, Carotid Artery Diseases, Cerebrovascular Disorders, Brain Diseases, Central Nervous System Diseases, Nervous System Diseases, Arterial Occlusive Diseases, Vascular Diseases, Cardiovascular Diseases, Pathological Conditions, Anatomical
Interventions
Gore Flow Reversal System, Gore Embolic Filter
Lead sponsor
W.L.Gore & Associates
Results first posted
2016-02-19

Source ClinicalTrials.gov

Source

Release
trial-comparisons-2026-03-23-0.1.0
Release manifest SHA-256
f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
AACT copy
2026-03-23
Tables read
outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet

Source ClinicalTrials.gov

Sources 2

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.

For software

Read this comparison from software.

The record is JSON. No key.

GET https://conductscience.org/api/comparisons/v1/NCT01343667-7597cdf5